Hilmet GC Tablet is a combination oral hypoglycemic agent containing Gliclazide 80 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class drug, primarily stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. This dual mechanism provides effective glycemic control in patients inadequately managed by diet and exercise alone. Hilmet GC is typically prescribed when monotherapy with either agent is insufficient or when a complementary approach is warranted. It is essential to monitor blood glucose levels regularly to avoid hypoglycemia, a potential risk associated with sulfonylureas. Metformin’s use requires caution in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often improve with continued therapy. Hilmet GC should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular medical supervision. Dose adjustments should be individualized based on therapeutic response and tolerability.